RAPT Therapeutics Announces Proposed Public Offering of Common Stock
June 14 2021 - 4:01PM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based biopharmaceutical company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in oncology and inflammatory
diseases, today announced that it has commenced an underwritten
public offering of $125 million of its common stock. In addition,
RAPT expects the underwriters to be granted a 30-day option to
purchase up to an additional $18.75 million of its common stock on
the same terms and conditions. All of the shares of common stock
are being offered by RAPT. The proposed offering is subject to
market conditions, and there can be no assurance as to whether or
when the proposed offering may be completed or as to the actual
size or terms of the proposed offering.
J.P. Morgan, SVB Leerink and Piper Sandler are acting as joint
lead book-running managers for the proposed offering. Cantor is
acting as book-running manager for the proposed offering.
The offering is being made pursuant to a shelf registration
statement, including a base prospectus, filed by RAPT with
the Securities and Exchange Commission (SEC), which was
declared effective by the SEC on November 16, 2020. The offering
may be made only by means of a prospectus supplement and
accompanying prospectus. A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available on
the SEC’s website located at www.sec.gov. When
available, electronic copies of the preliminary prospectus
supplement and the accompanying prospectus may also be obtained
from: J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at
prospectus-eq_fi@jpmorgan.com or by telephone at (866) 803-9204;
SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, by email at
syndicate@svbleerink.com or by telephone at (800) 808-7525, ext.
6105; or Piper Sandler & Co., 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, Attention: Prospectus Department, by email
at prospectus@psc.com or by telephone at (800) 747-3924.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or jurisdiction.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based
biopharmaceutical company focused on discovering, developing and
commercializing oral small molecule therapies for patients with
significant unmet needs in oncology and inflammatory diseases.
Utilizing its proprietary discovery and development engine, RAPT is
developing highly selective small molecules designed to modulate
the critical immune drivers underlying these diseases. RAPT has
discovered and advanced two unique drug candidates, FLX475 and
RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for
the treatment of cancer and inflammation, respectively. RAPT is
also pursuing a range of targets that are in the discovery stage of
development.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to RAPT’s expectations
regarding the completion, timing and size of the proposed public
offering. These statements are subject to significant risks and
uncertainties and actual results could differ materially from those
projected. RAPT cautions investors not to place undue reliance on
the forward-looking statements contained in this release. These
risks and uncertainties include, without limitation, risks and
uncertainties related to market conditions, the risk that the
proposed public offering will not be consummated on the terms or in
the amounts contemplated or otherwise, and the satisfaction of
customary closing conditions related to the proposed public
offering. Risks and uncertainties relating to RAPT and its business
can be found in the “Risk Factors” section of RAPT’s Form 10-Q for
the quarter ended March 31, 2021, filed with the SEC on May 11,
2021, and in the preliminary prospectus supplement related to the
proposed public offering filed with the SEC on June 14, 2021. RAPT
undertakes no duty or obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or changes in RAPT’s expectations,
except as required by law.
Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
Media Contact:Aljanae
Reynoldsareynolds@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Sep 2023 to Sep 2024